文章核心观点 - 科恩·米尔斯坦律师事务所正调查泽纳斯生物制药公司潜在证券欺诈索赔，敦促受影响投资者联系律所讨论法律权利和赔偿选项 [1] 调查相关情况 - 律所调查泽纳斯生物制药公司2024年9月首次公开募股中购买股票的投资者的潜在证券欺诈索赔 [1] - 受影响投资者可点击链接了解加入集体诉讼信息，或联系律所合伙人莫莉·J·鲍文 [2][3] 诉讼指控内容 - 美国马萨诸塞州区联邦地方法院近期提起的集体诉讼指控，泽纳斯生物制药公司及其关键利益相关者在注册声明中夸大公司财务运营期限，违反联邦证券法 [4] - 公司IPO定价为每股17美元，向公众出售超1320万股，但数周后承认只能维持12个月运营，仅为最初预计24个月的一半，导致股价暴跌 [5] - 截至2025年4月15日，公司股价收于8.72美元，较发行价下跌近49% [5] 重要截止日期 - 购买泽纳斯生物制药公司IPO股票并遭受重大损失的投资者，需在2025年6月16日前申请担任首席原告，首席原告代表所有集体成员监督诉讼，不参与也可分享潜在赔偿 [6] 律所相关介绍 - 科恩·米尔斯坦是美国领先的原告律师事务所，在证券诉讼领域经验丰富，拥有超100名律师分布在8个办公室 [7] - 该律所曾为受骗投资者挽回数十亿美元损失，获《法律500强》《法律360》等机构认可 [7] - 2024年，该律所作为联合首席律师在富国银行证券诉讼案中帮助挽回超10亿美元损失 [7]

NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statemen ...

文章核心观点 Bragar Eagel & Squire, P.C.宣布对Zenas BioPharma提起集体诉讼，指控其IPO注册声明存在虚假或误导性陈述，投资者可在2025年6月16日前申请成为首席原告 [1][3] 诉讼相关 - 集体诉讼已在美国马萨诸塞州区联邦地方法院对Zenas BioPharma提起，代表在2024年9月该公司首次公开募股相关注册声明和招股说明书下购买或获得其证券的所有个人和实体 [1] - 投资者需在2025年6月16日前向法院申请成为诉讼的首席原告 [1] 指控内容 - 公司IPO注册声明包含虚假或误导性陈述，未披露公司大幅高估用现有现金和IPO预期净收益维持运营的时间 [3] - 被告公开声明在所有相关时间均存在重大虚假和误导性，且准备疏忽 [3] 联系方式 - 若购买Zenas BioPharma股票遭受损失、是长期股东、有相关信息或想了解更多索赔事宜，可通过邮箱investigations@bespc.com、电话(212) 355 - 4648或填写联系表单联系Brandon Walker或Marion Passmore，无需费用和义务 [4] 律所信息 - Bragar Eagel & Squire, P.C.是全国知名律师事务所，在纽约、加利福尼亚和南卡罗来纳设有办公室，代表个人和机构投资者参与商业、证券等复杂诉讼 [5] - 律所官网为www.bespc.com [5][7]

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a “clinical stage global biopharmaceutical company committed to being a leader in the development a ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration sta ...

WASHINGTON, April 21, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential claims on behalf of investors who purchased securities of Zenas BioPharma, Inc. (NASDAQ:ZBIO) pursuant and/or traceable to the Company's September 2024 initial public offering ("IPO"). Investors who suffered significant losses are encouraged to contact the firm. [Click here for information about joining the class action] CASE OVERVIEW: Zenas BioPharma, a clinical-stage biopharmaceutical company, held ...

LOS ANGELES, April 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents issued in connection with its initial public offering ("IPO") conducted on September 13, 2024, are encouraged to contact the ...

SAN DIEGO, April 21, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit.  Captioned Buathongsri v. Zen ...

NEW YORK, April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=143839&from=4CLASS PERIOD: This lawsu ...

文章核心观点 - 罗兵咸盖勒鲁德曼及陶德律师事务所宣布泽纳斯生物制药公司IPO相关证券购买者或收购者若受损，可在2025年6月16日前申请成为集体诉讼首席原告，该诉讼指控公司及相关方违反1933年证券法 [1] 案件相关信息 - 泽纳斯生物制药是临床阶段生物制药公司，在IPO中以每股17美元价格出售超1300万股 [2] - 集体诉讼指控IPO发售文件存在重大虚假或误导性内容，未披露公司夸大运营资金可用时长 [3] - 2024年11月12日公司季度报告显示运营资金可用12个月，而非IPO注册声明中所说24个月 [4] - 截至2025年4月15日收盘，公司股价8.72美元，较IPO价格下跌48.7% [4] 首席原告流程 - 1995年《私人证券诉讼改革法案》允许相关投资者申请成为首席原告 [5] - 首席原告通常是对假定集体所寻求救济有最大财务利益且具代表性和充分性的申请人 [5] - 首席原告代表所有其他集体成员指导诉讼，可选择律所，投资者分享潜在赔偿不依赖担任首席原告 [5] 律所信息 - 罗兵咸盖勒鲁德曼及陶德律师事务所是全球领先的证券欺诈和股东诉讼律师事务所 [6] - 过去五年中有四年在ISS证券集体诉讼服务排名中位列第一，2024年为投资者追回超25亿美元 [6] - 律所拥有200名律师，分布在10个办公室，曾获得多项重大证券集体诉讼赔偿，包括有史以来最大的72亿美元 [6]